At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
Bortezomib +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Bortezomib, Lenalidomide, and 3 other interventions for Multiple Myeloma. Completed, enrolled 46 participants across 8 sites.
Detailed Summary
This research study is evaluating a combination of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc., Celgene
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartDec 2015
Primary CompletionDec 2021
Study CompletionOct 2025
TodayJul 2026
First PostedMay 12, 2015
Enrollment StartDec 1, 2015
Primary CompletionDec 1, 2021
Study CompletionOct 1, 2025
TodayJul 2, 2026
Enrollment to primary: 6 yearsPosted 11.1 years ago
Interventions
Bortezomibdrug
Lenalidomidedrug
Dexamethasonedrug
Stem Cell Mobilizationprocedure
Autologous Stem Cell Transplantprocedure